Novel influenza A (H1N1) is a new flu virus of swine origin that was first detected in Mexico and the United States in March and April, 2009. The first novel H1N1 patient in the United States was confirmed by laboratory testing at CDC on April 15, 2009. The second patient was confirmed on April 17, 2009. It was quickly determined that the virus was spreading from person-to-person. On April 22, CDC activated its Emergency Operations Center to better coordinate the public health response. On April 26, 2009, the United States Government declared a public health emergency.
It’s thought that novel influenza A (H1N1) flu spreads in the same way that regular seasonal influenza viruses spread; mainly through the coughs and sneezes of people who are sick with the virus.
Upp Technology announced the selection of their irms|EM Emergency Management Software by the Vermont Department of Health to provide statewide distribution of emergency supplies, including H1N1 antivirals, personal protection equipment (PPE) and other medical supplies and equipment whether from the CDC's Strategic National Stockpile (SNS) or other inventory reserves.
Independent testing performed at ATS Labs, an internationally recognized antimicrobial testing laboratory, demonstrated that PerfectClean with Micrillon wipers eliminated biological contaminants in a very short time. This promising technology has the potential to impact disinfection practices in the healthcare market.
With the height of seasonal flu season approaching and the pandemic of H1N1 in the headlines, CHG Healthcare Services has designed and mobilized a campaign to keep employees informed of the latest flu trends affecting their offices.
CEL-SCI Corporation, a late-stage oncology company and a developer of vaccines and therapeutics for the prevention and treatment of infectious diseases, announced today that it has retained the services of an international Contract Research Organization (CRO) to run CEL-SCI's upcoming Phase III clinical trial in advanced primary head and neck cancer with the Company's lead product candidate, Multikine®.
With flu season in full swing and the threat of H1N1 looming, demand for vaccines is at an all-time high. Although those vaccines are expected to be effective, University of Missouri researchers have found further evidence that some over-the-counter drugs, such as aspirin and Tylenol, that inhibit certain enzymes could impact the effectiveness of vaccines.
The current wave of pandemic H1N1 appears to have peaked, with four weeks of declines in several key indicators, the Centers for Disease Control and Prevention said Monday. Despite the decrease, the outbreak is continuing to take a heavy toll of hospitalizations and deaths, especially among children.
TriCore Reference Laboratories of Albuquerque, N.M., reported at a recent user meeting results of their research collaboration with Roche Applied Science in which they evaluated Roche´s new MagNA Pure 96 System for use in nucleic acid purification. The evaluation focused on the Roche system’s ability to process specimens for pathogen testing.
Akonni Biosystems, a molecular diagnostics (MDx) company focused on providing rapid and highly scalable solutions for infectious disease testing, today announced receipt of a $3.2M Phase II SBIR grant from the National Institutes of Health (NIH).
Hard to Treat Diseases' (HTDS; http://www.htdsmedical.com/) operating subsidiary Mellow Hope finalized contract details with one of the largest manufacturer of intravenous medication in India.
The Department of Health reminded Pennsylvanians they can begin making appointments today to be vaccinated against the H1N1 flu virus.
Just because a vaccine is available doesn't mean people will choose to be inoculated, according to new UofT research published amid widespread public confusion around the merit of H1N1 flu shots.
Novavax, Inc. announced today it has completed enrollment in the Phase II clinical study of its trivalent seasonal influenza (2008/2009 recommended strains) VLP vaccine candidate in healthy adults 60 years of age or older (older adults). This randomized, double-blind, active-controlled study is comparing the safety, tolerability and immunogenicity of two different doses (15 mcg and 60 mcg) of Novavax's trivalent seasonal influenza VLP vaccine to a commercially available trivalent inactivated vaccine, TIV (Fluzone®).
NanoViricides, Inc., reports that the Company has filed its quarterly report with the SEC on November 23rd.
The U.S. Food and Drug Administration today approved Agriflu for people ages 18 years and older to prevent disease caused by influenza virus subtypes A and B.
GTA parents and children gathered at an African-style clinic in downtown Toronto today, where World Vision released a poll that showed most Canadians (84%) think it's great that a lot of focus is placed on immunizing Canadian children against the H1N1 flu and other diseases. They (79%) want to see just as much focus on immunizing children in poor countries.
ALDA Pharmaceuticals Corp. (TSX VENTURE:APH)(OTCBB:APCSF) ("the Company" or "ALDA") announces that it has entered into an agreement with Shoppers Drug Mart Corporation ("Shoppers") that will make the Company's T36® Antiseptic Hand Sanitizer available in over 1,170 Shoppers Drug Mart and Pharmaprix stores across Canada.
The world's leading vitamin D experts say that raising your levels of "the sunshine vitamin" this winter might be the best way to help your body naturally raise its resistance to all forms of the flu virus - including the H1N1 swine flu virus.
The World Vision clinic, modeled after a typical African community clinic, will stand in sharp contrast to the now-common sight of parents and children receiving the care they need at Canadian H1N1 flu shot clinics.
Biotech firm Replikins Ltd., which has analyzed the H1N1 virus' genomic data from the 1918 pandemic through the prediction, outbreak, and progress of the current H1N1 pandemic, today issued its latest biochemical analysis of the virus.
The WHO is looking into reports that patients with "severely suppressed immune systems" in Britain and the U.S. developed resistance Tamiflu, which is used to treat the symptoms of H1N1 (swine flu), a spokesman for the organization said Tuesday, Reuters reports.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.